Astellas Pharma Inc. ALPMY Stock
Astellas Pharma Inc. Price Chart
Astellas Pharma Inc. ALPMY Financial and Trading Overview
| Astellas Pharma Inc. stock price | 10.07 USD |
| Previous Close | 16.33 USD |
| Open | 16.18 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 16.04 - 16.18 USD |
| 52 Week Range | 12.82 - 16.91 USD |
| Volume | 47.27K USD |
| Avg. Volume | 59.4K USD |
| Market Cap | 29.16B USD |
| Beta (5Y Monthly) | 0.537164 |
| PE Ratio (TTM) | 29.851852 |
| EPS (TTM) | 0.2 USD |
| Forward Dividend & Yield | 0.44 (2.67%) |
| Ex-Dividend Date | March 30, 2023 |
| 1y Target Est | 17.09 USD |
ALPMY Valuation Measures
| Enterprise Value | -272288628736 USD |
| Trailing P/E | 29.851852 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.01920099 |
| Price/Book (mrq) | 0.019344984 |
| Enterprise Value/Revenue | -0.179 |
| Enterprise Value/EBITDA | -0.731 |
Trading Information
Astellas Pharma Inc. Stock Price History
| Beta (5Y Monthly) | 0.537164 |
| 52-Week Change | 10.33% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 16.91 USD |
| 52 Week Low | 12.82 USD |
| 50-Day Moving Average | 15.59 USD |
| 200-Day Moving Average | 14.65 USD |
ALPMY Share Statistics
| Avg. Volume (3 month) | 59.4K USD |
| Avg. Daily Volume (10-Days) | 45.43K USD |
| Shares Outstanding | 1.81B |
| Float | 1.79B |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.029% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 60 |
| Trailing Annual Dividend Yield | 367.42% |
| 5 Year Average Dividend Yield | 247.00% |
| Payout Ratio | 0.739 |
| Last Split Factor | 125:100 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 6.50% |
| Operating Margin (ttm) | 17.55% |
| Gross Margin | 81.01% |
| EBITDA Margin | 24.52% |
Management Effectiveness
| Return on Assets (ttm) | 6.95% |
| Return on Equity (ttm) | 6.65% |
Income Statement
| Revenue (ttm) | 1.52T USD |
| Revenue Per Share (ttm) | 834.4 USD |
| Quarterly Revenue Growth (yoy) | 16.60% |
| Gross Profit (ttm) | N/A |
| EBITDA | 372.4B USD |
| Net Income Avi to Common (ttm) | 98.71B USD |
| Diluted EPS (ttm) | 0.54 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 376.84B USD |
| Total Cash Per Share (mrq) | 208.24 USD |
| Total Debt (mrq) | 75B USD |
| Total Debt/Equity (mrq) | 4.97 USD |
| Current Ratio (mrq) | 1.446 |
| Book Value Per Share (mrq) | 833.291 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 327.77B USD |
| Levered Free Cash Flow (ttm) | 216.46B USD |
Profile of Astellas Pharma Inc.
| Country | United States |
| State | N/A |
| City | Tokyo |
| Address | 2-5-1, Nihonbashi-Honcho |
| ZIP | 103-8411 |
| Phone | 81 3 3244 3000 |
| Website | https://www.astellas.com |
| Industry | Drug Manufacturers-General |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals in the Japan, United States, and internationally. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company has a joint research agreement with Veneno Technologies Co. Ltd. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Q&A For Astellas Pharma Inc. Stock
What is a current ALPMY stock price?
Astellas Pharma Inc. ALPMY stock price today per share is 10.07 USD.
How to purchase Astellas Pharma Inc. stock?
You can buy ALPMY shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Astellas Pharma Inc.?
The stock symbol or ticker of Astellas Pharma Inc. is ALPMY.
Which industry does the Astellas Pharma Inc. company belong to?
The Astellas Pharma Inc. industry is Drug Manufacturers-General.
How many shares does Astellas Pharma Inc. have in circulation?
The max supply of Astellas Pharma Inc. shares is 1.79B.
What is Astellas Pharma Inc. Price to Earnings Ratio (PE Ratio)?
Astellas Pharma Inc. PE Ratio is 50.35000000 now.
What was Astellas Pharma Inc. earnings per share over the trailing 12 months (TTM)?
Astellas Pharma Inc. EPS is 0.2 USD over the trailing 12 months.
Which sector does the Astellas Pharma Inc. company belong to?
The Astellas Pharma Inc. sector is Healthcare.